159 related articles for article (PubMed ID: 12234168)
1. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
Webb IJ; Friedberg nW; Gribben JG; Fisher DC; Spitzer T; Neuberg D; Jallow H; Kim H; Houde H; Monroy R; Schmittling R; Freedman AS
Biol Blood Marrow Transplant; 2002; 8(8):429-34. PubMed ID: 12234168
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Lynch JC; Atkinson K; Juttner C; Hanania CE; Bociek G; Armitage JO
Biol Blood Marrow Transplant; 2001; 7(12):680-7. PubMed ID: 11787531
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
[TBL] [Abstract][Full Text] [Related]
5. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.
Rambaldi A; Borleri G; Dotti G; Bellavita P; Amaru R; Biondi A; Barbui T
Blood; 1998 Mar; 91(6):2189-96. PubMed ID: 9490708
[TBL] [Abstract][Full Text] [Related]
6. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
7. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
8. Selection and immunomagnetic purging of peripheral blood CD34+ cells for autologous transplantation in B-cell non-Hodgkin's lymphomas.
Pichert G; Schmitter D; Widmer L; Jost LM; Kurrer MO; Maurer R; Stahel RA
Ann Oncol; 1998 Jan; 9(1):51-4. PubMed ID: 9541683
[TBL] [Abstract][Full Text] [Related]
9. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
Després D; Flohr T; Uppenkamp M; Baldus M; Hoffmann M; Huber C; Derigs HG
J Hematother Stem Cell Res; 2000 Aug; 9(4):557-64. PubMed ID: 10982256
[TBL] [Abstract][Full Text] [Related]
10. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
14. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
15. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S
Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022
[TBL] [Abstract][Full Text] [Related]
16. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
17. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Joyce RM; Kraser CN; Tetrealt JC; Giallombardo N; McDermott D; Levine J; Umiel T; Regan M; Hurley D; Uhl L; Avigan D
Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.].
Gutiérrez-Aguirre CH; De la Garza-Salazar F; Cantú-Rodríguez O; González-Llano Ó; Jaime-Pérez JC; Mancias-Guerra C; García-Sepúlveda R; Salazar-Riojas R; Gómez-Almaguer D
Gac Med Mex; 2016 Oct; 152(Suppl 2):57-65. PubMed ID: 27792717
[TBL] [Abstract][Full Text] [Related]
19. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
20. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]